Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase <scp>III</scp> randomised clinical trial
Abstract Aims To evaluate the immunogenicity, efficacy, and safety of a biosimilar insulin glulisine candidate (T‐Glu) compared to the reference product (R‐Glu) in patients with...